Hidradenitis Suppurativa

Povorcitinib in Patients With Moderate to Severe Hidradenitis Suppurativa: 54-Week Efficacy and Safety Results From the STOP-HS1 and STOP-HS2 Phase 3 Studies Martina L. Porter, MD, Antonio Martorell, MD, PhD, Christopher J. Sayed, MD, Falk G. Bechara, MD, Hadar Lev-Tov, MD, MAS, Jennifer L. Hsiao, MD, John W. Frew, MBBS, MMed, MSc, PhD, Christos C. Zouboulis, MD, PhD, Joslyn S. Kirby, MD, MS, MEd, Huiling Zhen, PhD, Leandro L. Santos, MS < PREVIOUS POSTER NEXT POSTER >

Bimekizumab Leads to Sustained Flare-Free Status in Moderate-to-Severe Hidradenitis Suppurativa: 3-Year Data from BE HEARD EXT Steven Daveluy, Haley B. Naik, Ziad Reguiai, Sayaka Yamaguchi, Pablo Fernández-Peñas, Bartosz Lukowski, Christina Crater, Nicola Tilt, Antonio Martorell < PREVIOUS POSTER NEXT POSTER > POSTER 43

Bimekizumab Efficacy by Patient Subgroups in Moderate-to-Severe Hidradenitis Suppurativa: 3-Year Phase 3 Results from BE HEARD EXT Christopher J. Sayed, Martina L. Porter, Alejandro Molina-Leyva, Jacek C. Szepietowski, Yosuke Ishitsuka, Evelina van Ree, Christina Crater, Tom Vaux, Georgios Kokolakis < PREVIOUS POSTER NEXT POSTER > POSTER 44